News & Updates
Filter by Specialty:

Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer
The first interim analysis of the phase III LEAP-012 study shows the potential of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) as a new treatment option for intermediate-stage hepatocellular carcinoma (HCC).
Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer
07 Jan 2025
Palbociclib plus ET prolongs survival in metastatic breast cancer
First-line endocrine therapy (ET) plus palbociclib (palb/ET) performs better than mono-chemotherapy in improving time to treatment failure (TTF) and progression-free survival (PFS) in women with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC), as shown by the results of the phase III PADMA trial.
Palbociclib plus ET prolongs survival in metastatic breast cancer
06 Jan 2025
T-DXd improves PFS in breast cancer with rapid progression
Treatment with trastuzumab deruxtecan (T-DXd) results in longer progression-free survival (PFS) in patients with hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC) compared with physician’s choice of chemotherapy, according to the results of the phase III DESTINY-Breast06 study presented at SABCS 2024. In addition, no new safety signals have been identified.
T-DXd improves PFS in breast cancer with rapid progression
06 Jan 2025
Ipilimumab plus nivolumab elicits response in mCRPC
Use of dual immune checkpoint inhibitors (ICIs), nivolumab and ipilimumab, exhibits responses in some molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC), including those with mismatch repair deficiency (dMMR), nonsynonymous tumour mutational burden ≥7.1 muts/Mb (hTMB), a BRCA2 mutation (BRCAm), or biallelic CDK12 inactivation (CDK12i).